![Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial) - ScienceDirect Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial) - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0002914918317338-gr2.jpg)
Usefulness of Rivaroxaban for Secondary Prevention of Acute Coronary Syndrome in Patients With History of Congestive Heart Failure (from the ATLAS-ACS-2 TIMI-51 Trial) - ScienceDirect
![PDF] The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis PDF] The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis](https://d3i71xaburhd42.cloudfront.net/32d1dd0e96918f7d38cc1a05cb6a983573e968e5/15-Table1-1.png)
PDF] The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis
![Rivaroxaban in Patients Stabilized After a ST-Segment Elevation Myocardial Infarction: Results From the ATLAS ACS-2–TIMI-51 Trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary Rivaroxaban in Patients Stabilized After a ST-Segment Elevation Myocardial Infarction: Results From the ATLAS ACS-2–TIMI-51 Trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary](https://ars.els-cdn.com/content/image/1-s2.0-S0735109713009376-gr5.jpg)
Rivaroxaban in Patients Stabilized After a ST-Segment Elevation Myocardial Infarction: Results From the ATLAS ACS-2–TIMI-51 Trial (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects with Acute Coronary
![ATLAS ACS 2-TIMI 51: Safety Endpoints - NOACs in Post-ACS Setting - Anticoagulation in the Post-Warfarin Era: Where Are We Today? ATLAS ACS 2-TIMI 51: Safety Endpoints - NOACs in Post-ACS Setting - Anticoagulation in the Post-Warfarin Era: Where Are We Today?](https://www.webedcafe.com/extern/program_media/amjmed.com/2013/anticoag3/figure_images/bhatt/figure25_w420.png)
ATLAS ACS 2-TIMI 51: Safety Endpoints - NOACs in Post-ACS Setting - Anticoagulation in the Post-Warfarin Era: Where Are We Today?
![PDF] Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. | Semantic Scholar PDF] Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/28cdc9f7ebf4529018a7c9ea31d2282fb44f4c13/3-Table1-1.png)
PDF] Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. | Semantic Scholar
![PDF) The "dual-pathway" strategy after acute coronary syndrome: Rivaroxaban and antiplatelet agents in the ATLAS ACS 2-TIMI 51 trial PDF) The "dual-pathway" strategy after acute coronary syndrome: Rivaroxaban and antiplatelet agents in the ATLAS ACS 2-TIMI 51 trial](https://www.researchgate.net/publication/262845959/figure/fig2/AS:272600425300009@1442004414644/Comparative-risk-for-clinically-significant-bleeding-or-death-MI-stroke-or-severe_Q320.jpg)
PDF) The "dual-pathway" strategy after acute coronary syndrome: Rivaroxaban and antiplatelet agents in the ATLAS ACS 2-TIMI 51 trial
![ATLAS ACS 2-TIMI 51: Treatment-emergent Fatal Bleeds and Intracerebral Bleeds - NOACs in Post-ACS Setting - Anticoagulation in the Post-Warfarin Era: Where Are We Today? ATLAS ACS 2-TIMI 51: Treatment-emergent Fatal Bleeds and Intracerebral Bleeds - NOACs in Post-ACS Setting - Anticoagulation in the Post-Warfarin Era: Where Are We Today?](https://www.webedcafe.com/extern/program_media/amjmed.com/2013/anticoag3/figure_images/bhatt/figure26_w420.png)
ATLAS ACS 2-TIMI 51: Treatment-emergent Fatal Bleeds and Intracerebral Bleeds - NOACs in Post-ACS Setting - Anticoagulation in the Post-Warfarin Era: Where Are We Today?
![Reduction of Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Rivaroxaban in ATLAS-ACS 2 TIMI 51 - ScienceDirect Reduction of Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Rivaroxaban in ATLAS-ACS 2 TIMI 51 - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0735109713014861-gr2.jpg)
Reduction of Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Rivaroxaban in ATLAS-ACS 2 TIMI 51 - ScienceDirect
![ATLAS ACS-2 TIMI 51: Stent thrombosis in Patients with Acute Coronary Syndromes treated with Rivaroxaban | tctmd.com ATLAS ACS-2 TIMI 51: Stent thrombosis in Patients with Acute Coronary Syndromes treated with Rivaroxaban | tctmd.com](https://d18mqtxkrsjgmh.cloudfront.net/public/styles/large_slide_teaser/public/2012-10/114971.png?itok=LYNVGjoK)
ATLAS ACS-2 TIMI 51: Stent thrombosis in Patients with Acute Coronary Syndromes treated with Rivaroxaban | tctmd.com
![PDF] Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. | Semantic Scholar PDF] Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/28cdc9f7ebf4529018a7c9ea31d2282fb44f4c13/4-Figure1-1.png)
PDF] Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. | Semantic Scholar
![ATLAS ACS 2-TIMI 51: Primary Efficacy Endpoint CV Death / MI / Stroke - NOACs in Post-ACS Setting - Anticoagulation in the Post-Warfarin Era: Where Are We Today? ATLAS ACS 2-TIMI 51: Primary Efficacy Endpoint CV Death / MI / Stroke - NOACs in Post-ACS Setting - Anticoagulation in the Post-Warfarin Era: Where Are We Today?](http://webedcafe.com/extern/program_media/amjmed.com/2013/anticoag3/figure_images/bhatt/figure19_w420.png)
ATLAS ACS 2-TIMI 51: Primary Efficacy Endpoint CV Death / MI / Stroke - NOACs in Post-ACS Setting - Anticoagulation in the Post-Warfarin Era: Where Are We Today?
![PDF) The "dual-pathway" strategy after acute coronary syndrome: Rivaroxaban and antiplatelet agents in the ATLAS ACS 2-TIMI 51 trial PDF) The "dual-pathway" strategy after acute coronary syndrome: Rivaroxaban and antiplatelet agents in the ATLAS ACS 2-TIMI 51 trial](https://i1.rgstatic.net/publication/262845959_The_dual-pathway_strategy_after_acute_coronary_syndrome_Rivaroxaban_and_antiplatelet_agents_in_the_ATLAS_ACS_2-TIMI_51_trial/links/560945e108ae4d86bb11a6a9/largepreview.png)
PDF) The "dual-pathway" strategy after acute coronary syndrome: Rivaroxaban and antiplatelet agents in the ATLAS ACS 2-TIMI 51 trial
![Frontiers | Low Dose Rivaroxaban for Atherosclerotic Cardiovascular Diseases: A Systematic Review and Meta-analysis Frontiers | Low Dose Rivaroxaban for Atherosclerotic Cardiovascular Diseases: A Systematic Review and Meta-analysis](https://www.frontiersin.org/files/Articles/608247/fphar-11-608247-HTML/image_m/fphar-11-608247-g005.jpg)
Frontiers | Low Dose Rivaroxaban for Atherosclerotic Cardiovascular Diseases: A Systematic Review and Meta-analysis
![The “Dual‐Pathway” Strategy after Acute Coronary Syndrome: Rivaroxaban and Antiplatelet Agents in the ATLAS ACS 2‐TIMI 51 Trial - Cohen - 2014 - Cardiovascular Therapeutics - Wiley Online Library The “Dual‐Pathway” Strategy after Acute Coronary Syndrome: Rivaroxaban and Antiplatelet Agents in the ATLAS ACS 2‐TIMI 51 Trial - Cohen - 2014 - Cardiovascular Therapeutics - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/ea1834bc-8ec6-4045-aad4-7d569cf9b683/cdr12083-fig-0001-m.jpg)
The “Dual‐Pathway” Strategy after Acute Coronary Syndrome: Rivaroxaban and Antiplatelet Agents in the ATLAS ACS 2‐TIMI 51 Trial - Cohen - 2014 - Cardiovascular Therapeutics - Wiley Online Library
![The “Dual‐Pathway” Strategy after Acute Coronary Syndrome: Rivaroxaban and Antiplatelet Agents in the ATLAS ACS 2‐TIMI 51 Trial - Cohen - 2014 - Cardiovascular Therapeutics - Wiley Online Library The “Dual‐Pathway” Strategy after Acute Coronary Syndrome: Rivaroxaban and Antiplatelet Agents in the ATLAS ACS 2‐TIMI 51 Trial - Cohen - 2014 - Cardiovascular Therapeutics - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/7dde0a25-e689-4c08-97fb-afa45673da0a/cdr12083-fig-0003-m.jpg)
The “Dual‐Pathway” Strategy after Acute Coronary Syndrome: Rivaroxaban and Antiplatelet Agents in the ATLAS ACS 2‐TIMI 51 Trial - Cohen - 2014 - Cardiovascular Therapeutics - Wiley Online Library
![PDF] The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis PDF] The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis](https://d3i71xaburhd42.cloudfront.net/32d1dd0e96918f7d38cc1a05cb6a983573e968e5/16-Table2-1.png)
PDF] The ATLAS ACS 2-TIMI 51 trial and the burden of missing data: (Anti-Xa Therapy to Lower Cardiovascular Events in Addition to Standard Therapy in Subjects With Acute Coronary Syndrome ACS 2-Thrombolysis
![ATLAS ACS 2-TIMI 51 - NOACs in Post-ACS Setting - Anticoagulation in the Post-Warfarin Era: Where Are We Today? ATLAS ACS 2-TIMI 51 - NOACs in Post-ACS Setting - Anticoagulation in the Post-Warfarin Era: Where Are We Today?](http://webedcafe.com/extern/program_media/amjmed.com/2013/anticoag3/figure_images/bhatt/figure17_w420.png)
ATLAS ACS 2-TIMI 51 - NOACs in Post-ACS Setting - Anticoagulation in the Post-Warfarin Era: Where Are We Today?
![European Society of Cardiology Chronic Coronary Syndromes Guidelines Review - European Medical Journal European Society of Cardiology Chronic Coronary Syndromes Guidelines Review - European Medical Journal](https://emj.emg-health.com/wp-content/uploads/sites/2/2019/10/Figure-1-2019-guidelines-for-the-management-of-CCS.png)